PregLem inks in-licensing deal with Merck Serono for Bentamapimod.
M2 PHARMA-August 11, 2010-PregLem inks in-licensing deal with Merck Serono for Bentamapimod(C)2010 M2 COMMUNICATIONS
11 August 2010 - Swiss specialty biopharmaceutical company PregLem said today it has signed a worldwide, exclusive in-licensing agreement for Bentamapimod, a novel, orally active, Jun Kinase Inhibitor (JNK-I AS602801) with Merck Serono,a division of Merck KGaA (ETR: MRK).
PregLem will develop the compound for the prevention of post-surgical abdominal adhesions and endometriosis in patients with tubal ligation or comparable effective contraception.
JNK-I (PGL5) is a potent anti-inflammatory agent which has been shown to reduce the disease burden in several pre-clinical models for endometriosis, and has the potential to be effective in addressing the causes of post-operative adhesions. Preclinical data show that the compound is an effective anti-inflammatory with anti-fibrotic properties, PregLem added.
PregLem said it plans to initiate a clinical proof of concept study and a Phase II study during 2011 for the prevention of post-surgical abdominal adhesions and/or endometriosis in patients with tubal ligation or comparable effective contraception.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||Aug 11, 2010|
|Previous Article:||Onset Medical gets FDA marketing clearance for additional size applications for SoloPath Endovascular Access Catheter.|
|Next Article:||Genzyme warns its production problems may last longer than expected.|